Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab or Lapatinib
Sponsor: Azienda Ospedaliera Ordine Mauriziano di Torino